Company Description
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States.
The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor.
The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.
Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Robert J. Bitterman |
Contact Details
Address: 11 Apex Drive, Suite 300a, Pmb 2006 Marlborough, Massachusetts 01752 United States | |
| Phone | (508) 767-3861 |
| Website | phiopharma.com |
Stock Details
| Ticker Symbol | PHIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001533040 |
| CUSIP Number | 71880W303 |
| ISIN Number | US71880W4024 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert J. Bitterman | President, Chief Executive Officer and Chairman |
| Caitlin Kontulis | Vice President of Finance and Administration and Secretary |
| Linda M. Mahoney | Senior Vice President of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 12, 2024 | 8-K | Current Report |
| Jul 5, 2024 | 8-K | Current Report |
| Jul 2, 2024 | 8-K | Current Report |
| Jul 1, 2024 | EFFECT | Notice of Effectiveness |
| Jun 21, 2024 | 8-K | Current Report |
| May 28, 2024 | 8-K | Current Report |
| May 20, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 20, 2024 | RW | Filing |
| May 17, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 17, 2024 | 424B5 | Filing |